AbbVie Provides Update on Phase 2 Results for Emraclidine in ...
Nov 11, 2024 · The EMPOWER clinical development program evaluated emraclidine in patients with schizophrenia who are experiencing an acute exacerbation in two adequately-powered, placebo-controlled Phase 2 trials, known as EMPOWER-1 (NCT05227690) and EMPOWER-2 (NCT05227703).
Emraclidine for Schizophrenia Fails to Meet Primary Endpoints in …
Nov 11, 2024 · Emraclidine once-daily, oral monotherapy treatment for adults with schizophrenia experiencing acute psychotic symptoms, failed to meet the primary endpoints in the 2 phase 2 EMPOWER trials.
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints ...
Nov 11, 2024 · On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.
AbbVie’s $9B bet collapses as closely watched schizophrenia drug …
Nov 11, 2024 · AbbVie lost about $40 billion in market value Monday morning after an experimental drug the company had bet heavily on failed two important clinical trials. The drug, called emraclidine, was developed by Pfizer spinout Cerevel Therapeutics, which AbbVie recently acquired for almost $9 billion.
AbbVie Provides Update on Phase 2 Results for Emraclidine in …
Nov 11, 2024 · AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an...
AbbVie Provides Update on Phase 2 Results for Emraclidine in …
Nov 11, 2024 · Emraclidine is a potential novel M4-selective positive allosteric modulator (PAM) in development for schizophrenia and Alzheimer's disease psychosis as a once-daily medication without the need...
AbbVie Provides Update on Phase 2 Results for Emraclidine in ...
Nov 11, 2024 · Emraclidine is a potential novel M4-selective positive allosteric modulator (PAM) in development for schizophrenia and Alzheimer's disease psychosis as a once-daily medication without the need...
A Month After Stunning Schizophrenia Fail, AbbVie’s Other
Dec 9, 2024 · The news comes almost one month to the day after AbbVie announced the shocking Phase II failure of another key Cerevel asset, emraclidine, which had been under development for schizophrenia.
AbbVie Drug Expected to Rival Bristol Myers’s New Schizophrenia …
Nov 11, 2024 · AbbVie schizophrenia drug candidate emraclidine failed to beat a placebo in two Phase 2 clinical trials. The drug, once projected to compete with Bristol Myers Squibb’s Cobenfy, is from...
AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine
11 hours ago · AbbVie is not giving up on emraclidine based on trial conduct and drug exposure observations in the failed phase trial in schizophrenia patients in late 2024.
- Some results have been removed